Jenburkt Pharmaceuticals Ltd vs Themis Medicare Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 17, 2026

Key Highlights

The Latest Trading Price of Jenburkt Pharmaceuticals Ltd is ₹ 1199 as of 15 May 15:30 . The P/E Ratio of Jenburkt Pharmaceuticals Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe P/E Ratio of Themis Medicare Ltd changed from 7.2 on March 2021 to 45.3 on March 2025 . This represents a CAGR of 44.46% over 5 years The Market Cap of Jenburkt Pharmaceuticals Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Market Cap of Themis Medicare Ltd changed from ₹ 257.55 crore on March 2021 to ₹ 1349 crore on March 2025 . This represents a CAGR of 39.28% over 5 years The revenue of Jenburkt Pharmaceuticals Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Themis Medicare Ltd for the Dec '25 is ₹ 96.93 crore as compare to the Sep '25 revenue of ₹ 82.97 crore. This represent the growth of 16.83% The ebitda of Jenburkt Pharmaceuticals Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Themis Medicare Ltd for the Dec '25 is ₹ 15.73 crore as compare to the Sep '25 ebitda of ₹ 1.89 crore. This represent the growth of 732.28% The net profit of Jenburkt Pharmaceuticals Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The net profit of Themis Medicare Ltd changed from ₹ 24.68 crore to ₹ 10.09 crore over 7 quarters. This represents a CAGR of -40.02% The Dividend Payout of Jenburkt Pharmaceuticals Ltd changed from 28.37 % on March 2021 to 24.76 % on March 2025 . This represents a CAGR of -2.69% over 5 yearsThe Dividend Payout of Themis Medicare Ltd changed from 14.84 % on March 2021 to 19.23 % on March 2025 . This represents a CAGR of 5.32% over 5 years .

About Jenburkt Pharmaceuticals Ltd

Jenburkt Pharmaceuticals Limited, incorporated in 1985, was formed a joint venture to diversify into the healthcare and pharmaceutical industry, by Bhuta family.
The Company is engaged in manufacturing and marketing of speciality and high quality pharmaceutical formulations and healthcare products. Presently, the Company manufactures and markets pharmaceutical formulations in India and internationally across 13 countries.
It has more than 1,000 stockists and their reach extends to 400,000+ pharmacies across the globe.
The organisation caters to government, semi-government institutions, missionary hospitals, public sector enterprises, etc. Apart from this. the Company operate manufacturing plant at Sihor-Gujarat, approved as per W.H.O (World Health Organisation) guidelines with current Good Manufacturing Practices (GMP) requirements.

About Themis Medicare Ltd

Themis Medicare Limited was formerly incorporated as 'Themis Chemicals Limited' in 1969.
The Company was originally promoted by Chemosyn and Medimpex but was taken over by a Group consisting of Shantibhai D Patel and K T Lakdawala who also have interests in Andhra Synthetics and Antibiotics, which was merged with Artemis Pharmaceuticals in April, 1993.
Thereafter, the name of the Company was changed to Themis Medicare Limited in 2001.
The Company is principally engaged in the business of manufacturing of finished formulations and synthetic Active Pharmaceutical Ingredients. In Mar.'95, the company came out with a public issue equity shares (premium : Rs 110) to finance the expansion-cum-modernisation of its synthetic bulk drug plant at Vapi, the setting up of a formulation unit at Lilora, Baroda as backward integration and to augment long-term working capital.

FAQs for the comparison of Jenburkt Pharmaceuticals Ltd and Themis Medicare Ltd

Which company has a larger market capitalization, Jenburkt Pharmaceuticals Ltd or Themis Medicare Ltd?

Market cap of Jenburkt Pharmaceuticals Ltd is 529 Cr while Market cap of Themis Medicare Ltd is 902 Cr

What are the key factors driving the stock performance of Jenburkt Pharmaceuticals Ltd and Themis Medicare Ltd?

The stock performance of Jenburkt Pharmaceuticals Ltd and Themis Medicare Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Jenburkt Pharmaceuticals Ltd and Themis Medicare Ltd?

As of May 17, 2026, the Jenburkt Pharmaceuticals Ltd stock price is INR ₹1199.6. On the other hand, Themis Medicare Ltd stock price is INR ₹97.94.

How do dividend payouts of Jenburkt Pharmaceuticals Ltd and Themis Medicare Ltd compare?

To compare the dividend payouts of Jenburkt Pharmaceuticals Ltd and Themis Medicare Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.